Report Tools

Biotechnology in Asia-Pacific

Published: August 2013 · Publisher: MarketLine
Biotechnology in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages32
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6775
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

Biotechnology in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Asia-Pacific biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

*The Asia-Pacific biotechnology market had total revenues of $79.2bn in 2012, representing a compound annual growth rate (CAGR) of 7.2% between 2008 and 2012.

*The pharmaceutical, medical, and biotechnology sector in Asia-Pacific is currently receiving high levels of private equity funding as the region is emerging as the new location for drug development and innovation.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 9.4% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $124.3bn by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Asia-Pacific

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Asia-Pacific

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Asia-Pacific economy

Key Questions Answered

What was the size of the Asia-Pacific biotechnology market by value in 2012?

What will be the size of the Asia-Pacific biotechnology market in 2017?

What factors are affecting the strength of competition in the Asia-Pacific biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up Asia-Pacific's biotechnology market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
#N/A
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market rivalry 2
Market Overview 6
Market definition 6
Market analysis 6
Market Data 7
Market value 7
Market Segmentation 8
Category segmentation 8
Geography segmentation 9
Market Outlook 10
Market value forecast 10
Five Forces Analysis 11
Summary 11
Buyer power 12
Supplier power 13
New entrants 14
Threat of substitutes 16
Degree of rivalry 17
Leading Companies 18
Merck & Co., Inc. 18
Mitsubishi Tanabe Pharma Corporation 21
Takeda Pharmaceutical Company Limited 24
Astellas Pharma Inc. 27
Appendix 30
Methodology 30
Industry associations 31
Related research 31

LIST OF TABLES
Table 1: Asia-Pacific biotechnology market value: $ billion, 2008–12 7
Table 2: Asia–Pacific biotechnology market category segmentation: $ billion, 2012 8
Table 3: Asia–Pacific biotechnology market geography segmentation: $ billion, 2012 9
Table 4: Asia-Pacific biotechnology market value forecast: $ billion, 2012–17 10
Table 5: Merck & Co., Inc.: key facts 18
Table 6: Merck & Co., Inc.: key financials ($) 19
Table 7: Merck & Co., Inc.: key financial ratios 19
Table 8: Mitsubishi Tanabe Pharma Corporation: key facts 21
Table 9: Mitsubishi Tanabe Pharma Corporation: key financials ($) 21
Table 10: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 22
Table 11: Mitsubishi Tanabe Pharma Corporation: key financial ratios 22
Table 12: Takeda Pharmaceutical Company Limited: key facts 24
Table 13: Takeda Pharmaceutical Company Limited: key financials ($) 25
Table 14: Takeda Pharmaceutical Company Limited: key financials (¥) 25
Table 15: Takeda Pharmaceutical Company Limited: key financial ratios 25
Table 16: Astellas Pharma Inc.: key facts 27
Table 17: Astellas Pharma Inc.: key financials ($) 28
Table 18: Astellas Pharma Inc.: key financials (¥) 28
Table 19: Astellas Pharma Inc.: key financial ratios 28

LIST OF FIGURES
Figure 1: Asia-Pacific biotechnology market value: $ billion, 2008–12 7
Figure 2: Asia–Pacific biotechnology market category segmentation: % share, by value, 2012 8
Figure 3: Asia–Pacific biotechnology market geography segmentation: % share, by value, 2012 9
Figure 4: Asia-Pacific biotechnology market value forecast: $ billion, 2012–17 10
Figure 5: Forces driving competition in the biotechnology market in Asia-Pacific, 2012 11
Figure 6: Drivers of buyer power in the biotechnology market in Asia-Pacific, 2012 12
Figure 7: Drivers of supplier power in the biotechnology market in Asia-Pacific, 2012 13
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Asia-Pacific, 2012 14
Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Asia-Pacific, 2012 16
Figure 10: Drivers of degree of rivalry in the biotechnology market in Asia-Pacific, 2012 17
Figure 11: Merck & Co., Inc.: revenues & profitability 20
Figure 12: Merck & Co., Inc.: assets & liabilities 20
Figure 13: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 22
Figure 14: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 23
Figure 15: Takeda Pharmaceutical Company Limited: revenues & profitability 26
Figure 16: Takeda Pharmaceutical Company Limited: assets & liabilities 26
Figure 17: Astellas Pharma Inc.: revenues & profitability 29
Figure 18: Astellas Pharma Inc.: assets & liabilities 29
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.